Apellis Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
APLS Apellis Pharmaceuticals Inc
AMD Advanced Micro Devices Inc
OTIS Otis Worldwide Corp
GME GameStop Corp
ECF Ellsworth Growth and Income Fund Ltd
SILK Silk Road Medical Inc
HLVX Hillevax Inc
AIZ Assurant Inc
NOTV Inotiv Inc
MYD BlackRock MuniYield
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that is focused on developing therapeutic compounds to treat disease through the inhibition of the complement system. The Company is developing pegcetacoplan with Sobi for systemic administration in several indications, including paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy, immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, cold agglutinin disease, and hematopoietic stem cell transplantation thrombotic microangiopathy. The Company's advanced clinical programs targeting component 3 with Phase III clinical trials of its lead product candidate, pegcetacoplan, in multiple indications. Pegcetacoplan is a conjugate of a compstatin analogue, formulated both for ophthalmological administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin.

Closing Price
$55.02
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Heavy Day)
Volume:
2,031,635

10-day average volume:
1,115,864
2,031,635

CSX Executive Vice President of Sales & Marketing to Address Stephens Annual Investment Conference

10:00 am ET November 10, 2022 (Globe Newswire) Print
CSX Executive Vice President of Sales & Marketing to Address Stephens Annual Investment ConferenceGlobeNewswireNovember 10, 2022

JACKSONVILLE, Fla., Nov. 10, 2022 (GLOBE NEWSWIRE) -- CSX Corp. (NASDAQ: CSX) executive vice president of sales & marketing, Kevin Boone, will address the Stephens Annual Investment Conference in Nashville, Tenn., Tuesday, November 15 at 10 a.m. Eastern time.

This address will be broadcast live via webcast at http://investors.csx.com. A replay will be available following the conclusion of this event. This announcement, as well as additional financial information, is available on the company's website at http://investors.csx.com.

About CSX

CSX, based in Jacksonville, Florida, is a premier transportation company. It provides rail, intermodal and rail-to-truck transload services and solutions to customers across a broad array of markets, including energy, industrial, construction, agricultural and consumer products. For nearly 200 years, CSX has played a critical role in the nation's economic expansion and industrial development. Its network connects every major metropolitan area in the eastern United States, where nearly two-thirds of the nation's population resides. It also links more than 240 short-line railroads and more than 70 ocean, river and lake ports with major population centers and farming towns alike. More information about CSX Corporation and its subsidiaries is available at www.csx.com. Like us on Facebook (http://facebook.com/OfficialCSX) and follow us on Twitter (http://twitter.com/CSX).

Contact:

Matthew Korn, CFA, Investor Relations

904-366-4515

Bryan Tucker, Corporate Communications

855-955-6397



Primary Logo

comtex tracking

COMTEX_418553987/2010/2022-11-10T10:00:01

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.